2019 opens to biggest pharma deal ever; Pfizer announces shutdown of two plants in India
If 2018 proved to be a big year for pharma deals, 2019 promises to be even bigger. The US government may have been partially shutdown, but some pharma companies were working through the holidays. The year opened with Bristol Myers Squibb acquirin...
FDA proposes limits on ‘sartan’ nitrosamine impurities; Text messages add new twist to US generic price fixing litigation
In our final Phispers of 2018, we bring you news on how the big pharmaceutical companies in the US plan to ring in the new year with price hikes. In the price fixing case, three drugmakers are being accused of working in collusion to hike the price...
Pfizer, GSK to merge consumer health units; J&J stock plummets after talc expose
The world of pharmaceuticals saw an eventful week when Pfizer and GSK decided to combine their consumer health units. The duo plans to demerge this consumer division after three years, through a UK stock market listing. An investigative report re...
PharmaFlow in November: Biopharma stock slump continues as dealmaking picks up
The Nasdaq Biotechnology Index tumbled almost 14 percent in October 2018 and is currently (as of December 19, 2018) down 19 percent from its October 1, 2018 high. Although it looks like the biopharma sector is heading for a volatile 2019, the...
America’s generic price fixing probe widens to 300 drugs; Rift between Ranbaxy’s Singh brothers gets physical
This week, Phispers brings you news from the US, India, China and France. In the US, the government’s probe into the alleged generic drug price fixing has now been expanded to include 300 drugs and 16 companies. In India, the slugfest betwe...
Valsartan may have been contaminated since 2011, says FDA warning letter to Huahai
Since July this year, a host of high blood pressure drugs got recalled globally once both the US Food and Drug Administration (FDA) and regulators in Europe learned that the valsartan API made by China’s Zhejiang Huahai Pharmaceuticals co...
Bayer to cut 12,000 jobs; GSK buys cancer drugmaker Tesaro for US$ 5 billion
This week, Phispers has news on German drug major Bayer, which has drawn out a revamp plan that includes plans to slash 12,000 jobs worldwide and restructuring of its R&D business. British drug major GSK vaulted into the commercial oncology mar...
Expose on medical device failures and outrage over birth of genetically-edited babies in China grips pharma world
This week, Phispers tells you how an exposé by the International Consortium of Investigative Journalists (ICIJ) on medical device failures prodded the FDA to overhaul its approval process. Revelation by a Chinese researcher on the birth of...
PharmaFlow in October: Deal making picks up; Pharma companies invest in capacity building
The year 2018 has witnessed a record-setting pace in approvals of new drugs. By early November, the US Food and Drug Administration (FDA) had approved 48 new drugs, as compared to a total of 46 new drugs approved in calendar 2017. This year, the ...
Mylan’s troubles run deep: US plant receives warning letter; EU suspends valsartan certificate of suitability
In August this year, American generic drug major Mylan posted disappointing second-quarter results and slashed its full-year guidance. During its earnings call, the company had said it has formed a strategic review committee to look...